Literature DB >> 27489337

Subjects With Extreme-Duration Type 1 Diabetes Exhibit No Structural or Functional Abnormality on Cardiac MRI.

Omar Asghar1, Christopher Miller2, Simon Ray2, Matthias Schmitt2, Rayaz A Malik3.   

Abstract

Entities:  

Year:  2016        PMID: 27489337      PMCID: PMC5033085          DOI: 10.2337/dc16-0760

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


× No keyword cloud information.
Medalists represent a unique group of survivors of over 50 years of type 1 diabetes (T1D) (1,2). A subgroup of Medalists, escapers, remains free of micro- and macrovascular complications. To date, there are no published studies on cardiac structure and function in these subjects. We have undertaken a comprehensive multiparametric cardiac MRI study (3,4) to quantify myocardial structure, function, deformation, perfusion, and fibrosis in a cohort of 13 subjects with extreme-duration T1D and 14 healthy control subjects (Table 1).
Table 1

Clinical characteristics and cardiac MRI data

Control subjectsT1DP
Clinical characteristics
 Age (years)54.6 ± 5.461.8 ± 7.60.009
 Diabetes duration (years)47.4 ± 5.1
 BMI (kg/m2)27.0 ± 3.128.1 ± 4.50.48
 Systolic blood pressure (mmHg)118 ± 11128 ± 150.051
 Diastolic blood pressure (mmHg)72 ± 1060 ± 140.014
 HbA1c (%)5.7 ± 0.48.3 ± 1.0<0.0001
 Total cholesterol (mmol/L)5.0 ± 0.744.6 ± 1.00.227
 LDL cholesterol (mmol/L)2.9 ± 0.62.1 ± 1.00.035
 HDL cholesterol (mmol/L)1.6 ± 0.42.1 ± 0.70.027
 Triglycerides (mmol/L)1.1 ± 0.50.9 ± 0.40.265
 eGFR (mL/kg/min)81 ± 972 ± 200.135
Cardiac MRI
 Volumetrics
  Left ventricular mass index [BSA] (g/m2)51.1 ± 10.741.0 ± 6.40.007
  Left ventricular ejection fraction (%)61.0 ± 6.463.1 ± 6.90.425
 Myocardial strain
  Longitudinal strain−16.0 ± 10.8−18.9 ± 5.50.394
  Longitudinal strain rate0.9 ± 0.91.2 ± 0.40.243
  Radial strain−34.3 ± 11.6−32.1 ± 17.70.707
  Radial strain rate1.3 ± 0.71.5 ± 0.50.412
  Circumferential strain−22.3 ± 2.6−24.9 ± 5.20.109
  Circumferential strain rate2.7 ± 5.71.4 ± 0.50.29
 MBF
  Rest (mL/min/g)0.75 ± 0.170.86 ± 0.240.177
  Stress (mL/min/g)2.07 ± 0.421.80 ± 0.350.094
  Stress/rest index2.81 ± 0.472.16 ± 0.660.006
 ECV
  ECV (%)0.27 ± 0.050.32 ± 0.040.01

BSA, body surface area; eGFR, estimated glomerular filtration rate.

Clinical characteristics and cardiac MRI data BSA, body surface area; eGFR, estimated glomerular filtration rate. The T1D group had a mean duration of diabetes of 47.4 ± 5.1 years (median 48.0 years). Eight participants had a history of retinopathy and 12 were receiving statin and ACE inhibitor therapy. The mean HbA1c over the previous 16 years was 8.3 ± 1.0% (69 ± 11 mmol/mol). The T1D group had higher systolic and lower diastolic blood pressure (P = 0.05, P = 0.01), lower LDL cholesterol (P = 0.04), and higher HDL cholesterol (P = 0.03). BMI, total cholesterol, triglycerides, and estimated glomerular filtration rate did not differ between the groups. We found no evidence of coronary artery disease or previous myocardial infarction on stress imaging and T1 mapping, respectively. Left ventricular mass index was significantly lower in the T1D group (P = 0.007), but there was no difference in left ventricular ejection fraction. Myocardial deformation as assessed by radial, circumferential, and longitudinal strain did not differ between the groups. Myocardial blood flow (MBF) at rest and during pharmacological stress did not differ between the groups; however, the MBF ratio (stress/rest), an index of coronary microvascular perfusion reserve, was significantly lower in the T1D group (P = 0.006). We did not find any correlation between myocardial perfusion reserve and markers of cardiac autonomic function. On T1 mapping, extracellular volume (ECV) was significantly higher in the T1D group than in the control group (P = 0.01). This is the first study to describe in detail the cardiac phenotype in a Medalist cohort. Using robust, validated, and reproducible three-dimensional modeling methods for volumetric and structural analyses, we demonstrate normal systolic and diastolic cardiac function in keeping with our recent echocardiographic study (5). There were no differences in MBF, but the stress/rest index was reduced, which is suggestive of coronary microvascular dysfunction. Coronary microvascular dysfunction may partly be mediated through cardiac autonomic dysfunction, but we found no correlation between myocardial perfusion reserve and cardiac autonomic function in our cohort. Quantitative assessment of myocardial ECV, a surrogate of myocardial fibrosis, shows much promise, and we have recently validated this in humans (3). ECV was increased in our Medalist group, which is suggestive of a very early fibrosis as there was no associated left ventricular mechanical dysfunction. Although our study had limited numbers, we believe the detailed cardiac MRI cardiac phenotyping in this unique cohort of extreme-duration patients with T1D provides considerable insight and confirms that these unique individuals are indeed protected from the long-term complications of diabetes. Clinicians responsible for the care of patients with long-duration diabetes should perform detailed cardiac assessment to aid risk stratification for cardiovascular complications.
  5 in total

1.  Medalists with extreme duration of type 1 diabetes exhibit only mild diastolic dysfunction and myocardial fibrosis.

Authors:  Andrew Fagan; Omar Asghar; Keith Pearce; Martin Stout; Simon G Ray; Matthias Schmitt; Rayaz A Malik
Journal:  Diabetes Care       Date:  2015-01       Impact factor: 19.112

2.  Characteristics of Type 1 diabetes of over 50 years duration (the Golden Years Cohort).

Authors:  S C Bain; G V Gill; P H Dyer; A F Jones; M Murphy; K E Jones; C Smyth; A H Barnett
Journal:  Diabet Med       Date:  2003-10       Impact factor: 4.359

3.  Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the joslin 50-year medalist study.

Authors:  Jennifer K Sun; Hillary A Keenan; Jerry D Cavallerano; Bela F Asztalos; Ernst J Schaefer; David R Sell; Christopher M Strauch; Vincent M Monnier; Alessandro Doria; Lloyd Paul Aiello; George L King
Journal:  Diabetes Care       Date:  2011-04       Impact factor: 19.112

4.  Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume.

Authors:  Christopher A Miller; Josephine H Naish; Paul Bishop; Glyn Coutts; David Clark; Sha Zhao; Simon G Ray; Nizar Yonan; Simon G Williams; Andrew S Flett; James C Moon; Andreas Greiser; Geoffrey J M Parker; Matthias Schmitt
Journal:  Circ Cardiovasc Imaging       Date:  2013-04-03       Impact factor: 7.792

5.  Voxel-wise quantification of myocardial blood flow with cardiovascular magnetic resonance: effect of variations in methodology and validation with positron emission tomography.

Authors:  Christopher A Miller; Josephine H Naish; Mark P Ainslie; Christine Tonge; Deborah Tout; Parthiban Arumugam; Anita Banerji; Robin M Egdell; David Clark; Peter Weale; Christopher D Steadman; Gerry P McCann; Simon G Ray; Geoffrey J M Parker; Matthias Schmitt
Journal:  J Cardiovasc Magn Reson       Date:  2014-01-24       Impact factor: 5.364

  5 in total
  1 in total

1.  Protection from neuropathy in extreme duration type 1 diabetes.

Authors:  Shazli Azmi; Maryam Ferdousi; Alise Kalteniece; Ioannis N Petropoulos; Georgios Ponirakis; Uazman Alam; Omar Asghar; Andrew Marshall; Adhithya Sankar; Andrew J M Boulton; Handrean Soran; Nathan Efron; Rayaz A Malik
Journal:  J Peripher Nerv Syst       Date:  2020-12-04       Impact factor: 3.494

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.